Helicobacter pylori 根除治疗的指示及其对处方和有效性的影响 (Hp-EuReg)
Samuel J Martínez-Domínguez1,2,3, Olga P Nyssen4, Ángel Lanas1,2,3
1Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
Helicobacter
|July 13, 2024
概括
治疗Helicobacter pylori的有效性因适应症而异,和前瘤病变的成功率更高. 四重疗法在大多数H.pylori根除的指示中是有效的.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 临床研究 临床研究
背景情况:
- 对于Helicobacter pylori研究的特定指示对治疗结果的影响尚不清楚.
- 了解这些影响对于优化H. pylori根除策略至关重要.
研究的目的:
- 评估H. pylori研究的不同适应症如何影响处方模式,治疗有效性,患者遵守性和耐受性.
- 分析整个欧洲H. pylori感染的现实管理.
主要方法:
- 欧洲胃肠病学家对H. pylori管理的前性非干预注册 (Hp-EuReg).
- 在2013-2023年期间,使用e-CRF AEG-REDCap.Cap.使用53636名先前未接受治疗的患者的分析.
- 通过修改的治疗意图分析来评估有效性.
主要成果:
- 经正常内镜检查的消化不良 (49%) 和未经检查的消化不良 (20%) 是最常见的症状.
- 治疗的有效性从87% (未经调查的消化不良) 到91% (十二指肠) 之间.
- 四重疗法 (基于比斯木和非比斯木) 在大多数适应症中实现了~90%的有效性;消化不良/群体的不良事件较高.
结论:
- 胃/十二指肠和前性病变在欧洲证明了H. pylori治疗的卓越有效性.
- 双 bismuth 和非 bismuth 四重疗法几乎为所有研究的适应症提供了最佳的结果.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
348
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
348
Peptic Ulcer Disease IV: Management
85
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
85
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
109
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
109
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
365
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
365
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
415
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
415
Gastritis III: Clinical Manifestations and Management
209
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
209


